GSK (NYSE:GSK) Shares Gap Down – Here’s Why

GSK PLC Sponsored ADR (NYSE:GSK) gapped down before the market opened on Wednesday . The stock had previously closed at $54.47, but opened at $50.00. GSK shares last traded at $50.8810, with a volume of 2,390,431 shares traded.

Key Stories Impacting GSK

Here are the key news stories impacting GSK this week:

• Positive Sentiment: Q1 beat and reaffirmed guidance: GSK reported quarterly earnings and revenue above estimates, with Specialty Medicines (HIV, oncology, respiratory) lifting sales and management reaffirming FY?2026 guidance — a key reason investors are buying the stock. Read More.
• Positive Sentiment: Regulatory progress: GSK Canada secured a priority review for bepirovirsen, a potential functional cure for chronic hepatitis B — this advances a late?stage asset that could add long?term upside if approved. Read More.
• Neutral Sentiment: Value narrative: Several outlets (Zacks) highlight GSK as an attractive long?term value play given yield, mid?teens P/E on recent earnings strength and a multi?year recovery story — this supports interest from income/value investors but is less immediate than near?term catalysts. Read More.
• Negative Sentiment: Alzheimer’s program failure: Alector?partnered Alzheimer’s asset linked to GSK failed in Phase 2, representing a setback for the company’s neuroscience ambitions and creating potential write?offs and pipeline uncertainty. This weighs on sentiment despite the quarter’s strength. Read More.
• Negative Sentiment: Analyst stance: JP Morgan reiterated an underweight rating with a modest £17 price target and says upside to earnings upgrades is limited absent pipeline successes and strong new?launch execution — a notable sell?side headwind for the stock. Read More.

Analysts Set New Price Targets

Several equities research analysts have weighed in on GSK shares. Citigroup reissued a “neutral” rating on shares of GSK in a research note on Monday, February 9th. TD Cowen reissued a “hold” rating on shares of GSK in a research note on Monday, February 9th. Morgan Stanley reissued an “underweight” rating on shares of GSK in a research note on Wednesday, January 14th. Weiss Ratings cut GSK from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, March 19th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of GSK in a research note on Friday, January 16th. One research analyst has rated the stock with a Buy rating, six have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Reduce” and an average target price of $53.00.

GSK Stock Performance

The stock has a market cap of $106.33 billion, a P/E ratio of 13.61, a PEG ratio of 2.98 and a beta of 0.46. The business has a 50 day moving average price of $55.78 and a 200 day moving average price of $51.62. The company has a quick ratio of 0.54, a current ratio of 0.82 and a debt-to-equity ratio of 0.92.

GSK (NYSE:GSK) last released its earnings results on Thursday, February 5th. The pharmaceutical company reported $0.68 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.04. The firm had revenue of $11.59 billion for the quarter, compared to analysts’ expectations of $8.48 billion. GSK had a return on equity of 45.90% and a net margin of 17.82%.The company’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.23 earnings per share. As a group, sell-side analysts expect that GSK PLC Sponsored ADR will post 4.88 EPS for the current year.

GSK Cuts Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 9th. Investors of record on Friday, May 15th will be paid a $0.44 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $1.76 annualized dividend and a yield of 3.4%. GSK’s dividend payout ratio is 50.81%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. IHT Wealth Management LLC lifted its holdings in GSK by 1.3% during the fourth quarter. IHT Wealth Management LLC now owns 15,010 shares of the pharmaceutical company’s stock worth $736,000 after buying an additional 188 shares during the period. Bogart Wealth LLC lifted its holdings in GSK by 15.3% during the first quarter. Bogart Wealth LLC now owns 1,508 shares of the pharmaceutical company’s stock worth $83,000 after buying an additional 200 shares during the period. Coston McIsaac & Partners lifted its holdings in GSK by 17.3% during the fourth quarter. Coston McIsaac & Partners now owns 1,395 shares of the pharmaceutical company’s stock worth $68,000 after buying an additional 206 shares during the period. First Horizon Corp lifted its holdings in GSK by 78.7% during the fourth quarter. First Horizon Corp now owns 536 shares of the pharmaceutical company’s stock worth $26,000 after buying an additional 236 shares during the period. Finally, Peoples Bank KS lifted its holdings in GSK by 6.3% during the fourth quarter. Peoples Bank KS now owns 5,030 shares of the pharmaceutical company’s stock worth $247,000 after buying an additional 300 shares during the period. Institutional investors own 15.74% of the company’s stock.

About GSK

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.